M Ketteler

Summary

Affiliation: Klinikum Coburg
Country: Germany

Publications

  1. doi request reprint [The kidneys and the vessels]
    M Ketteler
    III Medizinische Klinik, Klinikum Coburg
    Dtsch Med Wochenschr 133:1844-7. 2008
  2. doi request reprint Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V)
    Patrick Biggar
    Klinikum Coburg, Nephrological Department, Ketschendorferstrasse 33, 96450 Coburg, Germany
    Expert Opin Pharmacother 11:2739-50. 2010
  3. doi request reprint Use of phosphate binders in chronic kidney disease
    Markus Ketteler
    Division of Nephrology, Klinikum Coburg GmbH, Coburg, Germany
    Curr Opin Nephrol Hypertens 22:413-20. 2013
  4. doi request reprint FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease
    Markus Ketteler
    Division of Nephrology, Klinikum Coburg GmbH, Coburg, Germany
    Nephrol Dial Transplant 28:821-5. 2013
  5. pmc Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
    Markus Ketteler
    Division of Nephrology, Klinikum Coburg, Coburg, Germany
    Nephrol Dial Transplant 27:3270-8. 2012
  6. pmc Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
    Markus Ketteler
    Division of Nephrology, Klinikum Coburg, Coburg, Germany
    Nephrol Dial Transplant 27:1942-9. 2012
  7. doi request reprint Mechanisms and treatment of extraosseous calcification in chronic kidney disease
    Markus Ketteler
    Department of Medicine III, Division of Nephrology, Klinikum Coburg GmbH, Ketschendorfer Straβe 33, 96450 Coburg, Germany
    Nat Rev Nephrol 7:509-16. 2011
  8. ncbi request reprint The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?
    Markus Ketteler
    Division of Nephrology, Coburg Clinic, Coburg Germany
    Int J Artif Organs 32:95-100. 2009
  9. pmc Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis
    Markus Ketteler
    Nephrologische Klinik, Klinikum Coburg gGmbH, Ketschendorfer Strasse 33, 96450 Coburg, Germany
    Clin J Am Soc Nephrol 3:1125-30. 2008
  10. doi request reprint Dietary and pharmacological control of calcium and phosphate metabolism in predialysis stages of chronic kidney disease
    Markus Ketteler
    Division of Nephrology, Klinikum Coburg, Ketschendorfer Strasse 33, Coburg, Germany
    Blood Purif 27:345-9. 2009

Collaborators

Detail Information

Publications50

  1. doi request reprint [The kidneys and the vessels]
    M Ketteler
    III Medizinische Klinik, Klinikum Coburg
    Dtsch Med Wochenschr 133:1844-7. 2008
  2. doi request reprint Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V)
    Patrick Biggar
    Klinikum Coburg, Nephrological Department, Ketschendorferstrasse 33, 96450 Coburg, Germany
    Expert Opin Pharmacother 11:2739-50. 2010
    ..Phosphorus control, one component of CKD metabolic derangements, is potentially related to impaired outcomes and has significant room for improvement...
  3. doi request reprint Use of phosphate binders in chronic kidney disease
    Markus Ketteler
    Division of Nephrology, Klinikum Coburg GmbH, Coburg, Germany
    Curr Opin Nephrol Hypertens 22:413-20. 2013
    ..In this regard, phosphate binders are considered the prime option; however, dietary phosphate restriction and intensified dialysis are also valuable supportive tools...
  4. doi request reprint FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease
    Markus Ketteler
    Division of Nephrology, Klinikum Coburg GmbH, Coburg, Germany
    Nephrol Dial Transplant 28:821-5. 2013
    ..Such studies not only help to continuously improve our understanding, but also especially sharpen our perception of how thin the line may be between adaptation and maladaptation in chronic disease scenarios...
  5. pmc Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
    Markus Ketteler
    Division of Nephrology, Klinikum Coburg, Coburg, Germany
    Nephrol Dial Transplant 27:3270-8. 2012
    ....
  6. pmc Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
    Markus Ketteler
    Division of Nephrology, Klinikum Coburg, Coburg, Germany
    Nephrol Dial Transplant 27:1942-9. 2012
    ..We conducted a multi-centre study in 12 countries to compare the safety and efficacy of paricalcitol and cinacalcet for the treatment of SHPT...
  7. doi request reprint Mechanisms and treatment of extraosseous calcification in chronic kidney disease
    Markus Ketteler
    Department of Medicine III, Division of Nephrology, Klinikum Coburg GmbH, Ketschendorfer Straβe 33, 96450 Coburg, Germany
    Nat Rev Nephrol 7:509-16. 2011
    ....
  8. ncbi request reprint The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?
    Markus Ketteler
    Division of Nephrology, Coburg Clinic, Coburg Germany
    Int J Artif Organs 32:95-100. 2009
    ..This overview will both discuss aspects of pathophysiology of phosphate regulation and current and future clinical treatement approaches...
  9. pmc Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis
    Markus Ketteler
    Nephrologische Klinik, Klinikum Coburg gGmbH, Ketschendorfer Strasse 33, 96450 Coburg, Germany
    Clin J Am Soc Nephrol 3:1125-30. 2008
    ..This study investigated the ability of sevelamer carbonate to control serum phosphorous in hyperphosphatemic patients who had chronic kidney disease and were not on dialysis...
  10. doi request reprint Dietary and pharmacological control of calcium and phosphate metabolism in predialysis stages of chronic kidney disease
    Markus Ketteler
    Division of Nephrology, Klinikum Coburg, Ketschendorfer Strasse 33, Coburg, Germany
    Blood Purif 27:345-9. 2009
    ..This assessment should include measurements of fractional phosphate excretion and phosphatonin levels to objectively judge and effectively correct phosphate overload...
  11. doi request reprint Review article: Getting the balance right: assessing causes and extent of vascular calcification in chronic kidney disease
    Markus Ketteler
    Division of Nephrology, Klinikum Coburg, Ketschendorfer Strasse 33, Coburg, Germany
    Nephrology (Carlton) 14:389-94. 2009
    ..This article attempts to provide an update on insights into the pathophysiology of vascular calcification processes and a subjective view of the clinical consequences of management of CKD patients at risk...
  12. ncbi request reprint beta2-microglobulin-derived amyloidosis: an update
    J Floege
    Division of Nephrology, University of Aachen, Aachen, Germany
    Kidney Int Suppl 78:S164-71. 2001
    ..Such factors, which have changed over the last years as part of general improvements in dialysis care, may explain why the prevalence of the amyloidosis appears to decrease...
  13. ncbi request reprint Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience
    P Biggar
    Klinikum Coburg, Coburg, Germany
    Clin Nephrol 69:185-92. 2008
    ..Our study determined the intravenous epoetin-beta dose necessary to maintain or to achieve hemoglobin targets after switching from darbepoetin-alpha...
  14. ncbi request reprint Calcification and the usual suspect phosphate: still guilty but there are other guys behind the scenes
    Markus Ketteler
    Division of Nephrology, RWTH University Hospital Aachen, Germany
    Nephrol Dial Transplant 21:33-5. 2006
  15. ncbi request reprint Imaging techniques in the diagnosis of dialysis-related amyloidosis
    M Ketteler
    Division of Nephrology, University Hospital of Aachen Technical University, Aachen, Germany
    Semin Dial 14:90-3. 2001
    ..In conclusion, scintigraphy for A beta(2)M with (111)In-labeled rh beta(2)M provides a homogeneous and safe recombinant protein source and represents a suitable detection method of beta(2)M amyloid deposits in dialysis patients...
  16. ncbi request reprint Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis
    Harm Peters
    Division of Nephrology, Charite, Campus Mitte, Humboldt University, Berlin, Germany
    J Hypertens 21:771-80. 2003
    ....
  17. ncbi request reprint Bone pain with scintigraphy suggestive of widespread metastases--do not forget phosphate
    Vincent M Brandenburg
    Division of Nephrology, University Hospital, Medical School, Aachen, Germany
    Nephrol Dial Transplant 17:504-7. 2002
  18. doi request reprint Relation of recurrence of atrial fibrillation after successful cardioversion to renal function
    Martin Schmidt
    Department of Cardiology, Klinikum Coburg, Coburg, Germany
    Am J Cardiol 105:368-72. 2010
    ..01) decreased renal function showed an increase in GFR if sinus rhythm was maintained at 1 month follow-up. In conclusion, impaired renal function was associated with an increased risk of AF recurrence after successful ECV...
  19. ncbi request reprint Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis
    Marc M H Hermans
    Department of Internal Medicine and Nephrology, Academic Hospital Maastricht, PO Box 5800, 6202 AZ, Maastricht, The Netherlands
    Nephrol Dial Transplant 21:1293-9. 2006
    ..In this study, the relation between serum fetuin-A concentration and parameters of aortic stiffness was investigated in patients with end-stage renal disease...
  20. pmc Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul Study
    Joachim H Ix
    Division of Nephrology, Department of Medicine, Box 0532, HSE 672, University of California, San Francisco, San Francisco, CA 94143 0532, USA
    Nephrol Dial Transplant 21:2144-51. 2006
    ..Whether fetuin-A concentrations are also lower in the setting of mild-to-moderate chronic kidney disease (CKD) is unknown...
  21. doi request reprint The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification
    Ellen C M Cranenburg
    VitaK, Maastricht University, Maastricht, The Netherlands
    J Vasc Res 45:427-36. 2008
    ..Here we report on the development of an ucMGP assay and the potential diagnostic utility of monitoring serum ucMGP levels...
  22. ncbi request reprint Fetuin-A and extraosseous calcification in uremia
    Markus Ketteler
    Department of Nephrology and Clinical Immunology, University Hospital Aachen, Germany
    Curr Opin Nephrol Hypertens 14:337-42. 2005
    ..The emerging role of fetuin-A deficiency as a risk factor in dialysis patients was documented in a cross-sectional study demonstrating a significant correlation with all-cause and cardiovascular mortality...
  23. ncbi request reprint Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD)
    Sharon M Moe
    Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Kidney Int 67:2295-304. 2005
    ..This suggests protective mechanisms, or naturally occurring inhibitors, of calcification may be important...
  24. ncbi request reprint Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS)
    Jorge B Cannata-Andia
    Servicio de Metabolismo Oseo y Mineral, Instituto Reina Sofia de Investigacion, Hospital Universitario Central de Asturias, Oveido, Spain
    J Nephrol 21:290-8. 2008
    ..To survey bone mineral disturbances in the hemodialysis (HD) population in Europe and current clinical practice in Europe for the prevention, diagnosis and treatment of secondary hyperparathyroidism (SHPT) in HD patients...
  25. ncbi request reprint After several years of witchhunting, can calcium-based phosphate binding be released on probation?
    Markus Ketteler
    Nephrol Dial Transplant 23:17-9. 2008
  26. ncbi request reprint Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index
    Marc M H Hermans
    Department of Internal Medicine and Nephrology, Academic Hospital Maastricht, Maastricht, The Netherlands
    Blood Purif 25:395-401. 2007
    ..Vascular calcifications are related to cardiovascular mortality and morbidity in dialysis patients. Limited data exist on the role of calcification inhibitors, such as matrix-carboxyglutamic acid protein (MGP) in dialysis patients...
  27. ncbi request reprint Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification
    Willi Jahnen-Dechent
    Department of Biomedical Engineering, Biointerface Laboratory, RWTH Aachen University Clinics, Pauwelsstrasse 30, 52074 Aachen, Germany
    J Mol Med (Berl) 86:379-89. 2008
    ..In particular, we discuss the roles of the plasma protein fetuin-A/alpha2HS-glycoprotein and the mineral-binding protein osteopontin in the prevention and possible regression of mineralization in disease...
  28. doi request reprint Is fetuin-A/alpha2-Heremans-Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease?
    Jonas Axelsson
    Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    Am J Nephrol 28:669-76. 2008
    ..We studied circulating AHSG (ELISA) and two common functional AHSG gene polymorphisms (at amino acids Thr248Met (C-T) and Thr256Ser (C-G) using Pyrosequencing) and related these to multiple components of the metabolic syndrome...
  29. ncbi request reprint Development of lumbar bone mineral density in the late course after kidney transplantation
    Vincent M Brandenburg
    Department of Nephrology, University Hospital, Rheinisch Westfälische Technische Hochschule Aachen, Aachen, Germany
    Am J Kidney Dis 40:1066-74. 2002
    ..Rapid bone loss is a frequent finding early after kidney transplantation. Only limited data are available on the bone mineral density (BMD) in long-term kidney transplant recipients...
  30. pmc Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study
    Joachim H Ix
    Division of Nephrology, Department of Medicine, Box 0532, HSE 672, University of California, San Francisco, San Francisco, CA 94143 0532, USA
    Circulation 115:2533-9. 2007
    ..Lower serum fetuin-A concentrations are associated with valvular calcification in persons with end-stage renal disease. Whether fetuin-A is associated with valvular calcification in other patient populations is unknown...
  31. ncbi request reprint Vascular calcification and fetuin-A deficiency in chronic kidney disease
    Ralf Westenfeld
    Department of Nephrology and Clinical Immunology, University Hospital Aachen, Aachen, Germany
    Trends Cardiovasc Med 17:124-8. 2007
    ..The emerging role of fetuin-A deficiency as a risk factor in dialysis patients was documented in cross-sectional studies demonstrating a significant correlation with all-cause and cardiovascular mortality...
  32. ncbi request reprint The fate of bone after renal transplantation
    Vincent M Brandenburg
    Department of Nephrology, University Hospital, Rheinisch Westfäilische Technische Hochschule, Aachen, Aachen, Germany
    J Nephrol 17:190-204. 2004
    ..However, it is yet unproven that they reduce the fracture risk. In patients with adynamic bone disease, bisphosphonate usage cannot be recommended, since this group of drugs could oversuppress bone metabolism...
  33. ncbi request reprint Vascular calcification in patients with end-stage renal disease
    Jurgen Floege
    Medizinische Klinik II, Klinikum der RWTH, Pauwelsstrasse 30, D 52074 Aachen, Germany
    Nephrol Dial Transplant 19:V59-66. 2004
    ..Yet, it remains unclear whether sevelamer HCl reduces vascular calcification by preventing episodes of hypercalcaemia and/or by reducing low-density lipoprotein (LDL)-cholesterol levels...
  34. ncbi request reprint Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation
    Vincent M Brandenburg
    Department of Nephrology, University Hospital, Rheinisch Westfälische Technische Hochschule RWTH Aachen, Germany
    Transplantation 77:1566-71. 2004
    ..Bone mineral density (BMD) decreases significantly early after renal transplantation. This prospective study was designed to evaluate the long-term lumbar BMD development...
  35. ncbi request reprint Vascular calcification in chronic kidney disease
    William G Goodman
    Division of Nephrology, UCLA Medical Center, Los Angeles, CA 90095, USA
    Am J Kidney Dis 43:572-9. 2004
  36. pmc The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification
    Cora Schafer
    Interdisciplinary Center for Clinical Research on Biochematerials, University Clinics, Aachen, Germany
    J Clin Invest 112:357-66. 2003
    ..Taken together, our data demonstrate a critical role of Ahsg as an inhibitor of unwanted mineralization and provide a novel therapeutic concept to prevent ectopic calcification accompanying various diseases...
  37. ncbi request reprint Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study
    Markus Ketteler
    Department of Nephrology and Immunology, University Hospital Aachen, Aachen, Germany
    Lancet 361:827-33. 2003
    ..We aimed to investigate the hypothesis that AHSG deficiency is directly related to uraemic vascular calcification...
  38. ncbi request reprint Novel insights into uremic vascular calcification: role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin
    Markus Ketteler
    Department of Nephrology and Clinical Immunology, University Hospital Aachen, Germany
    Blood Purif 20:473-6. 2002
    ....
  39. ncbi request reprint Selective inhibition of inducible nitric oxide synthase enhances intraglomerular coagulation in chronic anti-Thy 1 nephritis
    Ralf Westenfeld
    Department of Medicine II, University Hospital Aachen, Pauwelsstrasse 30, D 52057 Aachen, Germany
    Kidney Int 61:834-8. 2002
    ..We investigated the effect of selective iNOS inhibition by l-N6-(1-iminoethyl)-lysine (L-NIL) administration on aThy 1-GN in LEW/Maa rats...
  40. ncbi request reprint Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification
    Rajnish Mehrotra
    Division of Nephrology and Hypertension, Harbor UCLA Medical Center, Torrance, California 90502, USA
    Kidney Int 67:1070-7. 2005
    ..Fetuin-A is the most potent circulating inhibitor of calcium phosphorus precipitation and, possibly, an important mediator of insulin resistance...
  41. ncbi request reprint Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse
    Markus Ketteler
    Department of Nephrology, University Hospital Aachen, Germany
    Nephrol Dial Transplant 20:673-7. 2005
  42. ncbi request reprint Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice
    Ralf Westenfeld
    Department of Nephrology and Clinical Immunology, University Hospital Aachen, Pauwelsstrasse 30, D 52057 Aachen, Germany
    Nephrol Dial Transplant 22:1537-46. 2007
    ..Chronic kidney disease (CKD) is associated with vascular and tissue calcification. The extent of vascular calcification has been identified as an independent risk factor of cardiovascular death in patients on haemodialysis...
  43. ncbi request reprint Inhibitors of calcification in blood and urine
    Georg Schlieper
    Department of Nephrology and Clinical Immunology, University Hospital Aachen, Aachen, Germany
    Semin Dial 20:113-21. 2007
    ..This review summarizes current experimental and clinical data underlining the biological importance of these calcification inhibitors...
  44. ncbi request reprint Spatial inhomogeneity of common carotid artery intima-media is increased in dialysis patients
    Marc M H Hermans
    Department of Internal Medicine and Nephrology, Academic Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands, and Department of Nephrology and Clinical Immunology, University Hospital RWTH, Aachen, Germany
    Nephrol Dial Transplant 22:1205-12. 2007
    ..With a new ultrasound technique CCA-IMT and IMT-inhomogeneity, a novel parameter of spatial variance of the IMT, were measured and related to traditional and non-traditional risk factors...
  45. ncbi request reprint Unclear fever 7 weeks after renal transplantation in a 56-year-old patient
    Anne Guetgemann
    Department of Nephrology and Clinical Immunology, University Hospital Aachen Pauwelsstrasse 30, D 52057 Aachen, Germany
    Nephrol Dial Transplant 21:2325-7. 2006
  46. ncbi request reprint Pathogenesis of vascular calcification in dialysis patients
    Markus Ketteler
    Department of Nephrology and Clinical Immunology, University Hospital Aachen, Pauwelsstrasse 30, D 52057 Aachen, Germany
    Clin Exp Nephrol 9:265-70. 2005
    ..This overview intends to summarize current knowledge of the scientific concepts involved in the pathogenesis of extraosseous calcification in ESRD...
  47. ncbi request reprint Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice
    Olivier Phan
    INSERM Unit 507, Necker Hospital, Paris, France
    Circulation 112:2875-82. 2005
    ....
  48. ncbi request reprint Lumbar bone mineral density in very long-term renal transplant recipients: impact of circulating sex hormones
    Vincent M Brandenburg
    Department of Nephrology, University Hospital, Rheinisch Westfälische Technische Hochschule Aachen, 52057, Aachen, Germany
    Osteoporos Int 16:1611-20. 2005
    ..The lumbar BMD decreased by -0.6+/-1.9% per year. In postmenopausal long-term renal transplant recipients, low estradiol levels were associated with accelerated bone loss...
  49. ncbi request reprint IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly
    Peter Stenvinkel
    Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Karolinska Institutet, Karolinska University Hospital at Huddinge, Stockholm, Sweden
    Kidney Int 67:1216-33. 2005
    ....
  50. ncbi request reprint Nitric oxide synthase isoform expression in acute versus chronic anti-Thy 1 nephritis
    Markus Ketteler
    Department of Medicine II, University Hospital Aachen, Pauwelsstrasse 30, D 52057 Aachen, Germany
    Kidney Int 61:826-33. 2002
    ..We investigated whether the glomerular expression pattern of nitric oxide synthase (NOS) isoforms could explain these substrain-related differences...